1. Home
  2. MDT vs VRTX Comparison

MDT vs VRTX Comparison

Compare MDT & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Medtronic plc.

MDT

Medtronic plc.

HOLD

Current Price

$100.36

Market Cap

125.3B

Sector

Health Care

ML Signal

HOLD

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

HOLD

Current Price

$468.22

Market Cap

115.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
MDT
VRTX
Founded
1949
1989
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
125.3B
115.7B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
MDT
VRTX
Price
$100.36
$468.22
Analyst Decision
Buy
Buy
Analyst Count
18
24
Target Price
$108.44
$497.77
AVG Volume (30 Days)
5.8M
1.2M
Earning Date
02-17-2026
02-09-2026
Dividend Yield
2.92%
N/A
EPS Growth
12.98
N/A
EPS
3.69
14.22
Revenue
$34,758,000,000.00
$11,723,300,000.00
Revenue This Year
$8.61
$11.01
Revenue Next Year
$5.86
$8.74
P/E Ratio
$26.38
$31.56
Revenue Growth
5.34
10.33
52 Week Low
$79.55
$362.50
52 Week High
$106.33
$519.68

Technical Indicators

Market Signals
Indicator
MDT
VRTX
Relative Strength Index (RSI) 59.61 63.29
Support Level $95.17 $443.12
Resistance Level $96.99 $455.99
Average True Range (ATR) 1.24 7.24
MACD -0.02 -0.72
Stochastic Oscillator 94.41 88.97

Price Performance

Historical Comparison
MDT
VRTX

About MDT Medtronic plc.

One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, ablation laser therapy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Share on Social Networks: